APRIL 8, 2024
Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis publishes its financial results for the year ended December 31,
APRIL 4, 2024
RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 resolutions presented by the Company have been adopted Biophytis announces the approval of all the
MARCH 22, 2024
Biophytis presented its phase 3 protocol in the treatment of sarcopenia Biophytis presented its phase 3 protocol aimed at demonstrating the potential of Ruvembri™ (20-hydroxyecdysone)
MARCH 18, 2024
Combined General Meeting of April 2, 2024 Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology
MARCH 15, 2024
Biophytis announces the implementation of a reverse stock split of its ordinary shares traded on Euronext Growth Biophytis announces that it has decided to implement
MARCH 12, 2024
Biophytis announces its participation in several events in Europe and the United States over the coming months Biophytis outcomes for patients suffering from age-related diseases,
MARCH 8, 2024
Biophytis presented the potential of Ruvembri™ in the treatment of Duchenne Muscular Dystrophy Biophytis presented the results of its recent clinical trials with Ruvembri™ at
FEBRUARY 22, 2024
“Live healthier longer” – Publication of a book on the medicine and science of longevity Biophytis announces the publication of a book written by Stanislas
JANUARY 4, 2024
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet Biophytis announces the publication of an